Merck & Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health.
In a statement, Merck & Co announced that Clyburn will take on the role effective immediately, and will lead all human health marketing and commercial operations.
He will be responsible for the company’s human health profit and loss (P&L) globally, reporting to Merck’s current chief executive officer Kenneth Frazier.
In January 2019, Clyburn became chief commercial officer for human health at Merck & Co.
Prior to this, he was president of the company’s global oncology business.
Clyburn joined Merck & Co in 2008 and during his time with the company, he has had responsibility for various global pharmaceutical franchises.
“I have tremendous respect for Frank’s strategic and operational excellence, and believe he is the perfect person to lead our ongoing success in human health,” said Robert Davis, executive vice president, global services and chief financial officer of Merck & Co.
“Frank’s leadership in rapidly expanding our oncology footprint and accelerating the growth of that business is unparalleled in our industry, exceeded only by his relentless dedication to helping patients. I look forward to continuing to work with him as we advance Merck’s mission to save and improve lives,” he added.